We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03086395
Recruitment Status : Withdrawn (Funding Unavailable)
First Posted : March 22, 2017
Last Update Posted : March 22, 2017
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Case Comprehensive Cancer Center

Brief Summary:

Patients with post transplant lymphoproliferative disorder (PTLD) that have been treated with at least one type of chemotherapy, but whose lymphoma is not responding or coming back after the previous treatment will be asked to participate in this study.

This clinical trial uses a drug called Obinutuzumab. The Food and Drug Administration (FDA) has approved Obinutuzumab for sale in the United States for certain diseases. Obinutuzumab is still being studied in clinical trials to learn more about what its side effects are and whether or not it is effective in the disease or condition being studied. Obinutuzumab is considered an investigational drug in this study

Obinutuzumab (GA101) is an antibody directed against cluster of differentiation antigen 20 (CD20). Antibodies are protein that are part of the immune system that can target cancer cells. Obinutuzumab sticks to a target called CD20. CD20 is an important molecule on some cancer cells (including non-Hodgkin lymphoma) and some normal cells of the immune system.

This study is being done to test if the study drug has an effect on post transplant lymphoproliferative disorder and to see how lymphoma will respond to the study drug.


Condition or disease Intervention/treatment Phase
Post-transplant Lymphoproliferative Disorder PTLD Drug: Obinutuzumab Phase 2

Detailed Description:

Primary Objective:

• To determine the overall response rate of obinutuzumab in relapsed/refractory post-transplant lymphoproliferative disorder (PTLD) in both solid organ transplant (SOT) and bone marrow transplant (BMT) patients

Secondary Objectives:

  • Complete remission (CR) rate
  • Duration of response (DOR)
  • Progression free survival (PFS)
  • Overall survival (OS)
  • Time to treatment failure (TTF)
  • Safety and tolerability of obinutuzumab

Patient Population:

Relapsed or refractory post-transplant lymphoproliferative disorder (PTLD) patients who have received at least one prior therapy

Study Design:

Phase II study of single agent obinutuzumab in relapsed/refractory (RR) post-transplant lymphoproliferative disorder (PTLD) in both SOT and BMT patients

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Estimated Study Start Date : April 1, 2017
Estimated Primary Completion Date : January 1, 2018
Estimated Study Completion Date : January 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Obinutuzumab
Patients will be treated with a total of 2 cycles of obinutuzumab.
Drug: Obinutuzumab
Patients will be treated with a total of 2 cycles of obinutuzumab. Cycle 1 obinutuzumab dose is 1000 mg given intravenously (IV) on day 1, 8, 15. Cycle #1 day #1 dose of 1000 mg of obinutuzumab will be administered over 2 days. During Cycle 1, Day 1, 100 mg will be administered. On the following day (Cycle 1, Day 2), 900 mg will be administered. During cycle 2 patients will receive a single dose of obinutuzumab1000 mg IV on day 1. Cycle #2 will be given 21 days after the first cycle.
Other Name: Gazyva




Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: Up to 36 months after beginning treatment ]

    Overall response rate will be estimated by the total number of patients who achieve a CR and PR divided by the total number of evaluable patients. Response will be assessed using CT scans according to the revised Cheson criteria

    • CR is defined as complete resolution of all clinically detectable disease and disease related symptoms that were present prior to therapy
    • PR is defined as at least 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses


Secondary Outcome Measures :
  1. Complete Response Rate [ Time Frame: Up to 36 months after beginning treatment ]
    CR is defined as complete resolution of all clinically detectable disease and disease related symptoms that were present prior to therapy. A post-treatment residual mass of any size is permitted as long as it is proton emission tomography (PET) negative. CR rate will be calculated by dividing the dividing the total number of patients who have achieved CR by the total number of patients who have achieved a CR and PR.

  2. Progression Free Survival [ Time Frame: Up to 36 months after beginning treatment ]
    Progression-free survival (PFS) is defined as the time from enrollment into the study to disease progression or death due to any cause. It may be defined as the date of documentation of a new lesion or enlargement of a previous lesion, or the date of the scheduled clinic visit immediately after radiologic assessment has been completed.

  3. Overall Survival [ Time Frame: Up to 36 months after beginning treatment ]
    The OS is defined as the time from enrollment to the time of death due to any cause. For a patient who is alive at the end of study follow-up, observation of OS is censored on the date of last contact.

  4. Duration of Response [ Time Frame: Up to 36 months after beginning treatment ]
    Duration of response (DOR) is defined as the time from first documentation of objective tumor response (CR or PR) to the time to tumor progression or death due to any cause.

  5. Time to Treatment Failure [ Time Frame: Up to 36 months after beginning treatment ]
    Time to treatment failure (TTF) is defined as the time from enrollment to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed relapsed/refractory post-transplant lymphoproliferative disorder
  • Relapsed/refractory disease with at least 1 prior chemotherapy regimen
  • Measurable disease ≥1.5 cm
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. ECOG 3 will be permitted if the decline in the performance status is attributed to the lymphoma
  • Able to sign the consent form
  • Adequate organ function

    • bilirubin ≤1.5 times upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times ULN or ≤5 times ULN for patients with document hepatic involvement with lymphoma
    • serum creatinine clearance >50 ml/min
    • absolute neutrophil count (ANC) ≥500/μL (unless documented bone marrow involvement with lymphoma)
    • hemoglobin >8 gm/dl
    • platelet count ≥50,000/μL (unless documented bone marrow involvement with lymphoma)

Exclusion Criteria:

  • Prior treatment with obinutuzumab
  • Pregnancy or breast feeding women
  • Current active malignancy other than PTLD, requiring active treatment
  • Presence of central nervous system (CNS) involvement
  • HIV positive patients
  • Myocardial infarction within the past 6 months
  • Patients with the following medical conditions that could affect their participation in the study:

    • any active acute or chronic or uncontrolled infection
    • liver disease including history of viral hepatitis B or C, evidence of cirrhosis, chronic active or persistent hepatitis
    • a known history of HIV
    • symptomatic cardiac disease, including congestive heart failure, coronary artery disease, and arrhythmias
  • Current therapy with chemotherapy or investigational agents within 4 weeks of start of study treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03086395


Sponsors and Collaborators
Case Comprehensive Cancer Center
Genentech, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Deepa Jagadeesh, MD, MPH Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Layout table for additonal information
Responsible Party: Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT03086395    
Other Study ID Numbers: CASE8Z15
First Posted: March 22, 2017    Key Record Dates
Last Update Posted: March 22, 2017
Last Verified: March 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Case Comprehensive Cancer Center:
relapsed
refractory
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Obinutuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents